Cargando…
SAT-455 Analysis of a Group of Prolactinomas Resistant to Treatment with Dopamine Agonists at a University Hospital in Buenos Aires, Argentina
Prolactinomas represent approximately 40-60% of all pituitary tumors. Dopamine agonists (DA) are the first-line treatment, with a 70-90% response. However, up to 10% are resistant (R) to DA. Our objectives were to describe the clinical, biochemical and imaging characteristics of a group of patients...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Endocrine Society
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552054/ http://dx.doi.org/10.1210/js.2019-SAT-455 |